Use of the Glycemia Risk Index at Hybrid Closed-Loop Initiation to Predict Combined International Glucose Targets at 12 Months: Results From the CIRDIA Study Group.

ABSTRACT:

Background

Hybrid closed-loop (HCL) therapy helps reaching efficacy and safety glucose targets (ESGT+) in persons with type 1 diabetes (PwT1D). We analyzed here the glycemia risk index (GRI) in PwT1D at HCL initiation (M₀) and at 12 months (M₁₂) and determined whether M₀GRI value and/or M₀GRI zone (A-B-C-D-E) could identify people reaching M₁₂ESGT+.

Methods

This was a retrospective study. Consecutive PwT1D who started HCL in a CIRDIA center were included after written consent. Glucose parameters were manually extracted from platforms at M₀ and M₁₂. ESGT+ meant reaching time in range (TIR) > 70% and glucose management indicator < 7% and time below range (TBR)^<70 < 4% and TBR^<54<

SUBMITTER: Picard S 

PROVIDER: S-EPMC12867718 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature